CompletedNCT01835093
Tipepidine Hibenzate for ADHD
About this title
Read the official source — NCT01835093Researchers studied Tipepidine Hibenzate to find out how it affected ADHD symptoms in people with ADHD.
Medication studyAges 6–17Japan
Understand this study
What did researchers investigate?
Researchers studied Tipepidine Hibenzate to find out how it affected ADHD symptoms in people with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- ChibaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateApril 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 10
- Sponsor
- Chiba University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Japan
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01835093
- Official title
Show the full official title
Tipepidine for ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chiba
Questions about this study
What did researchers investigate?
Researchers studied Tipepidine Hibenzate to find out how it affected ADHD symptoms in people with ADHD.
Who is behind this study?
The study sponsor is Chiba University, a university.
Did this study involve medication?
Yes. The study involved medication, including Tipepidine Hibenzate.
Who was this study for?
Listed age limits: 6 years to 17 years.
